Amylin Analogs Market Outlook 2030:
Amylin is basically a peptide hormone that is inducted with pancreatic beta-cell and is thus deficient in diabetic population. The hormone acts as a satiety agent while delaying gastric emptying. It also assists the insulin in controlling post meal high glucose levels Amylin Analogs are thus injectable drugs used to treat both Type-I and Type-II diabetes. Advantages of using the drug include low blood sugar levels, weight loss, enhanced digestion and suppression in the release of glucagon from the stomach. However, there are a few side effects associated with the usage of amylin analogs including vomiting, nausea and heart burn. Some of the major amylin analogs are pramlintide, smylin, etc.
Amylin analogs market is segmented based on type of diabetes such Type I and Type II diabetes with Asia Pacific witnessing higher number of cases of the later and North America topping the former. With regards to end users, hospitals and pharmacy stores top the list owing to being avenues for highest sales. Lately, owing to COVID-19 restrictions and overall move towards ecommerce, online pharmacy sales have shot up significantly too.
COVID-19 Impact Analysis
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the amylin analogs market.
Top Impacting Factors
- Growing burden of diabetes on the industrialized economies around the world with their role as global players and the subsequent need of advanced therapeutic drugs towards its treatment is a major factor driving growth of amylin analogs market.
- Impending unmet needs regarding advancements in healthcare infrastructure in high populace economies like India and China which experience higher diabetic population is another factor driving inception of new players in the industry and growth in overall amylin analogs market share.
- Increasing number of awareness initiatives regarding diabetes, its types, causes and treatment by governments across the globe is yet another factor driving the amylin analogs market growth.
- Shift of public policies towards developing enhanced healthcare supply chains owing to COVID-19 is prompting frequent product developments and clinical trials. This in turn is anticipated to affect amylin analogs market as well.
- Adoption of ecommerce as an alternative to traditional pharmacy stores during times of COVID-19 and beyond is likely to increase sales of amylin analogs as Omni channel strategy holds the capability to provide the customer base with beyond expectation service levels.
- However, higher cost of development and distribution associated with the drug is likely to hamper growth especially in rogue nations with less support from the ruling government.
Key Market Trends
- North America is likely to retain its position as the market leader when it comes to amylin analogs owing to higher proportion of diabetic patients combined with higher levels of disposable income, higher awareness and basic healthcare facilities at the disposal.
- Amylin analogs market is forecasted to increase two fold in Asia Pacific region in the next 1- years owing to rise in demand from Type I diabetic population residing in the region coupled with advancements in analog technology through massive collaborations between regional players such as Hindanol, etc.
- Recently, Novo Novardisk announced their new amylin analog product by the name of Rybelsus towards treatment of Type-2 diabetic patients.
- In 2019, Novo Novardisk also announced opening of a new amylin analog manufacturing facility in Kalundborg, Denmark for rapid penetration into North European market.
- Research and development is also underway regarding development of long term solution for treatment of diabetes. This includes development of artificial pancreas with the idea gaining rapid popularity owing to support from United States Food and Drug Administration (USFDA)
Key Benefits of the Report
- This study presents the analytical depiction of the amylin analogs industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the amylin analogs market share.
- The current market is quantitatively analyzed to highlight the amylin analogs growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.
Questions Answered in the Amylin Analogs Report
- Which are the leading players active in the amylin analogs market?
- How is each segment of the market expected to grow during the forecast period?
- What are the adoption trends for the amylin analogs market in emerging economies and established economies across the world?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What are the impacts of COVID-19 in the industry?
- What is amylin analogs?
- What is the amylin analogs market prediction in the future?
- What are the current trends and predicted trends?
Amylin Analogs Market Report Highlights
| Aspects | Details |
 By Diabetes Type |
|
 By End User |
|
 By Region |
|
 Key Market Players | Lantus, Boehringer Ingelheim, Eli Lilly and Company, Trulicity, AstraZeneca, Sanofi, Jardiance Ltd., Novo Nordisk, Soliqua, Victoza |
Loading Table Of Content...
